US 8474228

I'll run targeted searches for this patent number, including any litigation/docket activity.

Let me check for any litigation or court docket activity involving this patent number.

US 8,474,228 — "Packaging systems and methods for transporting vials"

Search scope note: I searched for the literal number 8474228 / 8,474,228. The results returned the correct patent; hits on "the '228 patent" in my searches referred to a different patent (U.S. 6,703,228, MIT/E8 Pharmaceuticals v. Affymetrix), which I have excluded. I found no district-court litigation, PTAB proceeding, or CAFC docket entry involving U.S. 8,474,228. That is an absence-of-evidence finding, not proof of non-existence.

Bibliographic data

Abstract (verbatim)

"A packaging system for transporting vials containing biological samples may comprise a first tray defining at least one first tray cavity; and a second tray defining at least one second tray cavity and configured to mate with the first tray. The packaging system may further comprise at least one first tray cavity and at least one second tray cavity, wherein the at least one first tray cavity and the at least one second tray cavity are configured to securely hold respective vials for transport, and to restrain caps on the respective vials during transport, wherein the at least one first tray cavity and the at least one second tray cavity oppose each other when the first tray and the second tray are mated together. The packaging system may also be configured to permit barcode scanning of vials held within the first tray cavity and the second tray cavity."

Independent claims — plain-language overview

Important structural point: the granted patent contains 10 claims, and only one independent claim — claim 1 (a method claim). Claims 2–10 all depend from claim 1. Notably, the published application US 2011/0132797 A1 had 36 claims including an independent apparatus claim (claim 1, "a packaging system…") and method claim 25. In the granted patent, the apparatus claims are not present, and the method claim was substantially rewritten and narrowed. I can confirm the claim sets differ; the prosecution history explaining why (e.g., examiner rejection, prior-art-based amendment) is not in the material I retrieved, so treat my characterization of the reason as uncertain.

Claim 1 (sole independent claim) — method of packaging vials:
A six-step method:

1. Put a capped vial containing a biological sample into a cavity of a first tray;
2. Put another capped vial into a cavity of a second tray;
3. Provide a friction fit between each cavity and both the vial and its cap (i.e., the cavity walls grip the cap as well as the tube body);
4. Mate the first and second trays together;
5. Independently scan a barcode on the vial in the first tray and the vial in the second tray; and
6. Place the mated trays inside a sleeve, such that a first air pocket forms between the first tray and the sleeve and a second air pocket forms between the second tray and the sleeve.

Practical reading: a two-piece plastic tray "clamshell" that grips capped sample tubes by friction, holds the caps on, can be barcode-read while vials are still in the trays, and then slides into a paperboard sleeve whose air gaps act as cushioning/thermal buffer — the point being ambient-temperature shipment of liquid biological samples without EPS coolers or coolant.

Dependent claims 2–10 (for context, not independent):

• 2 — the air pockets create a thermal buffer.
• 3 — sample is a liquid biological sample.
• 4 — sample is at ambient temperature.
• 5 — vials disposed laterally in the cavities.
• 6 — vials disposed substantially wholly within the cavities.
• 7 — pluralities of vials in pluralities of cavities in each tray.
• 8 — mating is by snapping the trays together.
• 9 — transporting the vials at ambient temperature.
• 10 — independently scanning a barcode on the bottom of each vial.

Specification highlights (context for the claims)

• Trays described as thermoform plastic, e.g., recycled PET (also HDPE/LDPE, PP, PS, PC, acrylate, PVC, ABS, cellulose, nylon, paperboard/cardboard).
• Cavities have a tapered neck portion that compresses the vial/cap to restrain the cap; optional protrusions snap over the vial to limit lateral movement (friction/snap retention).
• Snap mating via engaging flaps 107 / receiving recesses 120 and engaging buttons 110 / receiving depressions 126, to resist twisting.
• Exemplary packaging dimensions: height ≈ 2.08 in, width ≈ 3.36 in, depth ≈ 1.45 in — sized for a 2D barcode reader.
• Air pockets in the sleeve act as both cushioning and thermal buffer; the sleeve may act as an opaque barrier to activate a scanner sensor.
• Experimental data (FIGS. 8a–9b): ambient shipment simulation (144 hr, 20–30 °C, drops/vibration/altitude) showed ~1 µL volume loss per sample and concentration changes of 0.49% (AbD Gex) and −0.10% (miRNA) for the plastic tray system — within ±10% acceptance criteria.

Uncertainties and source-data inconsistencies I did not "auto-correct"

1. Litigation: No 2026 (or any) CAFC docket activity found for 8,474,228, and no district-court case naming it. I cannot rule out sealed or unindexed proceedings.
2. Priority-date discrepancy: Google Patents lists the priority date as 2009-12-08, while a Unified Patents family listing shows 2009-12-07 for US-8474228-B2. I am reporting both literally rather than harmonizing them.
3. Google Patents family-linkage anomaly: The Google Patents page for US 8,474,228 lists "Related Child Applications" and a "Priority to" entry for US 14/261,558 / US 11,731,682 B2, "Seat attachment for a stroller" (priority 2008-12-04). This is plainly unrelated subject matter to a vial packaging patent and appears to be a dataset/linkage error, but per the literal-interpretation rule I am flagging it rather than silently dropping it. I have not verified it against the official USPTO PatentCenter record.
4. Claim-set change in prosecution: Confirmed as a fact from the two documents; the reason for cancellation of the apparatus claims is not established by my sources.
5. "Assignee" nuance: Assignment records list "Life Technologies Corporation," with the inventor assignment executed 2009-12-07 to 2009-12-08. Current ownership after the Thermo Fisher acquisition chain is not established by these sources (Thermo Scientific products are cited throughout the specification, but the specification's product references are not an ownership statement).

Sources: https://patents.google.com/patent/US8474228/en ; https://uspto.report/patent/grant/8474228 ; https://patents.justia.com/patent/20110132797 ; https://www.patents-review.com/a/20110132797-packaging-systems-methods-transporting-vials.html

I'll research litigation involving U.S. Patent No. 8,474,228 across patent litigation databases.

Let me search more targeted patent litigation databases for this specific patent.

Litigation Search: U.S. Patent No. 8,474,228

Bottom Line

I found no litigation involving U.S. Patent No. 8,474,228. Based on the sources I was able to query, there do not appear to be any known patent infringement suits, declaratory judgment actions, PTAB proceedings, or appeals asserting or challenging this specific patent.

Because I could not run the exact faceted queries I would have liked (my search access was exhausted before I could directly hit the Unified Patents litigation caselist, CourtListener's docket search, or PACER), please treat this as a reasoned negative finding with moderate confidence, not a certified all-clear.

Important: Near-Miss Numbers — Do NOT Confuse These

My searches surfaced several patents with visually similar numbers that are unrelated to the target. I flag these explicitly so they are not mistaken for US 8,474,228:

None of these related to the target, and none of the litigation attached to them involved Life Technologies' vial-packaging patent.

What US 8,474,228 Actually Is

• Title: Packaging systems and methods for transporting vials
• Assignee: Life Technologies Corp. (now part of Thermo Fisher Scientific)
• Inventors: Nicholas Adair, Joselito Crespo, Allen Perry, Paul Russell
• Filing/priority date: December 8, 2009
• Grant date: July 2, 2013
• Status: Active (per Google Patents), adjusted expiration July 31, 2030; 12th-year maintenance fee paid December 17, 2024
• Family: US 12/633,751; also EP2509887 and WO2011072078 (both shown as not active/withdrawn)

This is a fairly narrow, single-family packaging patent. The Google Patents record for it lists only prior-art citations, "cited by" references, and family/status data — no litigation events, no PTAB proceedings, and no CAFC activity are recorded there.

Sources Consulted and Their Limits

Recommended Next Steps to Confirm

To convert this from a "no evidence found" finding into a verified negative, the following should be checked directly:

1. Unified Patents litigation caselist — search by patent number 8474228 (https://portal.unifiedpatents.com/litigation/caselist)
2. CourtListener RECAP / docket search — full-text search for "8,474,228" and "8474228"
3. PACER — no free full-text patent search, but a party-name sweep for Life Technologies and Thermo Fisher in D. Del., E.D. Tex., W.D. Tex., N.D. Cal., and D. Mass. could reveal any unindexed assertion
4. USPTO Patent Trial and Appeal Board (PTAB) API/portal — confirm no IPR/PGR/CBM naming this patent
5. CAFC — confirm no appeal involving this patent

Honest Caveat

If a suit involving this patent exists, it would most plausibly be a Life Technologies / Thermo Fisher infringement action against a competitor in the sample-storage or cold-chain packaging space (e.g., a maker of Matrix-style vial racks or transport trays). I have no evidence such a suit exists, and I am not asserting that one does. I am explicitly declining to fabricate case names, numbers, jurisdictions, or outcomes for a patent I could not connect to any docket. Unless one of the direct-source checks above turns up a filing, the accurate answer is: no known litigation.

PTAB / AIA Trial Landscape — U.S. Patent No. 8,474,228

Canonical source checked: the structured "PTAB proceedings on file" block in this prompt (USPTO Open Data Portal ingest) — returns zero AIA trial proceedings for US 8,474,228. Supplemental web searching (PTAB E2E web index, Google Patents litigation/PTAB tabs, general web queries pairing the patent number with "IPR," "PTAB," "petition," and the patent title) surfaced no IPR, PGR, or CBM petition or decision naming this patent.

Proceedings overview

Total AIA trial proceedings on file: 0 (0 active, 0 with claims invalidated, 0 with claims sustained, 0 settled, 0 institution denials). Bottom line for a defendant: there is no PTAB record either way. Nothing has been canceled — all ten claims stand as issued — but nothing has been tested, either, so there is zero § 315(e) estoppel on the books and every invalidity ground you can plead is still on the table. This is an untested patent, not a hardened one; the absence of any IPR after 13+ years of enforceability is a mild signal that it has not been aggressively asserted against well-capitalized targets, not a signal that it has survived attack.

No proceedings to report

No proceeding block is populated. Accordingly, I have no petitioner name, filing date, judge panel, institution decision, Final Written Decision, settlement, or appeal to report for this patent. Per the operating rules, I am not inventing proceeding numbers to fill the section.

What I verified and how (searches run 2026-09-17):

I could not independently confirm the docket-level absence via the PTAB E2E portal UI (see links below); the ODP block plus the negative search results are the basis for the "no PTAB activity" conclusion. If you need a litigation-grade clearance, pull the Patent Trial and Appeal Board's E2E record directly: https://ptacts.uspto.gov/ptacts/ and the decisions library at https://www.uspto.gov/patents/ptab/decisions.

Defensive value (zero-proceeding gloss): because no IPR has reached a Final Written Decision, no petitioner or privy is estopped under § 315(e)(2), and no claim has been canceled, narrowed, or held unpatentable. You are free to file the first IPR (subject to the § 315(b) one-year bar running from service of a complaint on you) and to run § 102/§ 103 and § 112 defenses in district court without any PTAB estoppel constraint.

Strategic summary

Claim status: all 10 claims UNTESTED. U.S. 8,474,228 issued 2013-07-02 with a single independent claim — method claim 1 — and dependent claims 2–10 (10 total; there is no independent apparatus claim, which matters tactically: there is no product claim to knock out to clear a device). Claim 1 recites disposing capped vials in first and second tray cavities, providing a friction fit between each cavity and both the vial and its cap, mating the trays, independently scanning barcodes, and disposing the mated trays in a sleeve so that first and second air pockets form between each tray and the sleeve. Claims 2–4 and 9 add the thermal-buffer, liquid-sample, ambient-temperature and ambient-transport limitations; claim 5–6 add lateral/wholly-disposed limitations; claim 7 covers pluralities (up to eight per tray); claim 8 recites a snap fit; claim 10 recites bottom-of-vial barcode scanning. All of these are method steps, which means infringement requires an accused actor performing the packaging/scanning/mating steps — a built-and-sold tray alone does not infringe. That is a real § 271(a)/(b) vulnerability for the patent owner that is entirely separate from validity, and no PTAB proceeding has ever addressed it. Patent term: status Active, adjusted expiration 2030-07-31, 12th-year maintenance fee paid 2024-12-17, so the patent is live and enforceable for roughly four more years.

Estoppel landscape: none exists. With no IPR/PGR FWD, § 315(e)(1)/(2) estoppel is not triggered against anyone. Every ground that was raised or reasonably could have been raised in a hypothetical IPR remains available to a defendant in district court — your only constraints are (i) the § 315(b) one-year clock if you have been served with a complaint of infringement, and (ii) § 325(a) (no IPR by a petitioner who previously filed a DJ action of invalidity) and § 315(a) (no IPR after filing a civil action challenging validity). Note also that because the application was filed 2009-12-08 — before the 2013-03-16 AIA first-inventor-to-file date — the patent is pre-AIA, so PGR is unavailable, CBM review is unavailable (and the CBM program is sunset), and IPR is the sole AIA trial vehicle. The strongest prior-art seeds are the references already of record that a petitioner would build on, cited on the face of the '228: US 4,990,900 (Transpan, "Biological sample vial transport tray"), US 5,040,678 (Transpan, "Biological sample transport container"), US 5,833,057 (Char, packaging/shipping biological fluid vials), US 6,161,687 (Technicor, "Vial container"), US 2007/0272587 (Nguyen, "Vial package"), and US 2010/0243509 (MeadWestvaco, containers with improved interior structures). The genuinely novel-sounding limitations to design around in a § 103 theory are the cap-restraining friction fit on both the vial and the cap, and the dual air pockets formed between each tray and the sleeve.

Pattern signals: nothing to pattern-match. No petitioner has filed even once against this patent, so there is no serial-IPR petitioner, no joinder activity, no defensive aggregator (nothing tying Unified Patents or a similar entity to this patent), and no Patent Owner appeal to the Federal Circuit — there is no appealable PTAB decision. The patent is held by Life Technologies Corporation (now part of Thermo Fisher Scientific) and the record shows only internal assignment and routine annuity payments; enforcement history is not visible in the sources I checked.

Two data-quality flags before you rely on the record. First, I found no indication of a continuation of the '228 application that issued as a vial-packaging patent; if a family member exists, it would change the assertion-surface analysis. Second, the Google Patents page for this patent contains clearly erroneous family entries: it lists a "Related Child Application" US 14/261,558 → US 8,955,869 and priority application US 16/903,292 → US 11,731,682 as continuations of the '228, both titled "Seat attachment for a stroller" / "Removable seat attachment for a stroller." Those are not vial-packaging patents and cannot be continuations of a 2009 vial-packaging application. Do not present that family linkage to a court or in an IPR without independent verification from USPTO PatentCenter — https://patentcenter.uspto.gov — it appears to be a data-merge artifact on the aggregator page.

Recommended next steps

1. If you are a defendant being asserted on: understand there is no FWD to link to — nothing has been canceled. Your validity play is to create the invalidity record, not to cite one. File an IPR on claim 1 (the only independent claim) if you are inside or can beat the § 315(b) one-year bar; claims 2–10 fall with it if claim 1 falls, and knocking out claim 1 collapses the entire patent.
2. Prioritize the claim-construction / divided-infringement angle in parallel. All claims are method claims and claim 1's final step (disposing mated trays in a sleeve with air pockets) plus the independent-scanning step are performed at different times by potentially different actors. A § 271(a)/(b)/(c) non-infringement position may be cheaper and faster than an IPR, and it is a defense PTAB cannot reach.
3. Docket hygiene before filing. Confirm no co-pending DJ action (§ 325(a)) or prior civil validity challenge (§ 315(a)); if a complaint has been served on you, calendar the § 315(b) deadline from the service date, not the filing date.
4. Verify the absence yourself at the source. Pull PTAB E2E (https://ptacts.uspto.gov/ptacts/) and CourtListener (https://www.courtlistener.com/?q=%228474228%22) for any recently filed petition or appeal the ODP ingest may lag. The ODP block is current as of the most recent ingest but is not a real-time docket.
5. Do not treat these negative findings as litigation clearance. This memo reports the absence of PTAB activity; it is not a validity opinion and does not address unasserted prior art, on-sale/§ 102(b) activity, or inequitable conduct.

I'll verify the assignment record and corporate ownership history before reconstructing the chain.

Let me check for any litigation, post-issuance transfers, and the inventors' affiliations.

Assignment Reconstruction — US 8,474,228 B2

"Packaging systems and methods for transporting vials" · App. 12/633,751 · Filed 2009-12-08 · Granted 2013-07-02

Verification note up front. Google Patents' legal-events feed for this patent shows exactly one recorded assignment — the original inventor→company transfer at filing. I was not able to complete a live pull of the USPTO Assignment Center record before my tool budget expired, so reel/frame below is taken from the Google Patents legal-events entry (which mirrors USPTO assignment data). Confirm at the Assignment Center search page: https://assignmentcenter.uspto.gov/ (search 8474228). No post-issuance assignment is recorded in any source I could reach.

Inventors

Employer is determinable because all four signed a single Assignment of Interest in favor of Life Technologies Corporation with signing dates 2009-12-07 to 2009-12-08 (recorded 2009-12-09, reel 023631/0689) — i.e., an at-filing, employee-to-employer assignment, the normal course for a corporate R&D filing. The subject matter (Matrix storage tubes, barcode-scanned sample shipping) is squarely within Life Technologies' consumables business.

Unusual patterns: none detected. My searches surfaced no evidence that any of the four departed the assignee within 12 months of filing, and no co-inventor assignment was recorded to any outside entity. This is a clean, conventional corporate-capture assignment — not the "inventors bail out early, then portfolio fire-sale" pattern. (Caveat: I could not run employment-history checks on each inventor; treat the "no departures" finding as unconfirmed, not affirmative.)

Original assignee

Life Technologies Corporation (Google Patents lists it as current assignee; original assignee per the recorded assignment).

• Product / practice: Yes — this is an operating life-sciences company. The patent's own examples name its commercial line: Thermo Scientific Matrix Storage Tubes, Matrix 2D Barcoded Storage Tubes, and SepraSeal / DuraSeal caps, plus the high-speed 2D barcode reader the package is dimensioned to sit on. The claimed article is the shipping tray/sleeve, not a vial, but it is the packaging for a product line the assignee actually sold.
• Primary business: Biotechnology tools — reagents, consumables, instruments (Invitrogen and Applied Biosystems brands).
• Current status: Acquired, then absorbed. Life Technologies Corporation was itself created 2008-11-21 by the merger of Invitrogen Corporation and Applied Biosystems Inc. (Invitrogen was the surviving legal entity, renamed Life Technologies; NASDAQ: LIFE). On 2014-02-03, Thermo Fisher Scientific (NYSE: TMO) completed its acquisition of Life Technologies for ~$13.6B cash plus ~$1.5B assumed net debt; Life Tech became the core of Thermo Fisher's new Life Sciences Solutions segment and the "Life Technologies" brand was retired. The patent is still docketed to "Life Technologies Corp" because a stock acquisition transfers patent title with the shares and generates no patent-by-patent assignment record — so the absence of a recorded 2014 assignment is expected, not suspicious.

Assignment timeline

2009-12-07 → 2009-12-08 (executed) / recorded 2009-12-09 — Reel 023631/0689

• Conveyance: Assignment (Assignment of Interest)
• Assignor: Nicholas J. Adair; Joselito T. Crespo; Allen M. Perry; Paul G. Russell (individually)
• Assignee: Life Technologies Corporation (Carlsbad, CA)
• Correspondent: Not disclosed in the retrieved record. The Google Patents legal-event entry gives only the reel/frame and the assignor/signing-date data, not the recording correspondent. I will not guess — this is a genuine gap, and I could not reach the Assignment Center page to fill it.
• Context: Routine at-filing employee-to-employer capture, executed one day before the 2009-12-08 filing date.

No further assignments recorded. No subsequent conveyance of any type (Assignment, Security Agreement, Merger, Change of Name, License, Release, Correction) appears for US 8,474,228 between grant in 2013 and today. The only other recorded activity is maintenance-fee payment: 4th year (2016-12-22), 8th year (2020-09-23), 12th year (2024-12-17), with adjusted expiration 2030-07-31.

Data-hygiene flag (do not treat as ownership records). Google Patents' family tables for this patent are contaminated by a mis-linked family ID. The "Priority Applications," "Related Child Applications," and legal-events rows attribute to this file:

• a priority date of 2008-12-04 (the application's actual priority date is 2009-12-08);
• child/continuation US 14/261,558 → US 8,955,869 B2, "Seat attachment for a stroller";
• US 16/903,292 → US 11,731,682 B2, "Removable seat attachment for a stroller" (styled in the feed as a 2020-06-16 priority event on this patent).

These are stroller patents with no relationship to vial packaging. They appear to be a family-ID collision on Google's side and should be excluded from any ownership chain. If any of these stroller records were ever relied on as a "child" of US 8,474,228, that reliance would be wrong.

Timeline diagram

timeline
    title Ownership of US 8474228
    2008 : Life Technologies formed from Invitrogen merger with Applied Biosystems
    2009 : Application filed by Life Technologies
         : Inventors assign rights reel 023631 0689
    2013 : Patent US 8474228 granted
    2014 : Life Technologies acquired by Thermo Fisher
    2016 : Fourth year maintenance fee paid
    2020 : Eighth year maintenance fee paid
    2024 : Twelfth year maintenance fee paid

(The 2014 Thermo Fisher event is a corporate stock acquisition with no recorded patent-level assignment; it is shown for completeness because it changed beneficial ownership.)

NPE / troll-pattern signals

Verdict

Insufficient data — with an operating-company ownership conclusion riding along.

Justification: The entire recorded chain consists of a single entry, reel 023631/0689 (executed 2009-12-07/08, recorded 2009-12-09), by which the four named inventors assigned the application to Life Technologies Corporation. No post-issuance assignment, security interest, merger recordation, license, or release exists in any source I could reach, and six years of maintenance-fee payments (through 2024-12-17) confirm the patent has been continuously held and actively maintained. Consequently there are zero strong NPE signals and zero weak ones — but because the record contains only the original assignment, your rubric directs the call to Insufficient data rather than a confident "operating-company assertion," which would additionally require evidence of the owner suing actual competitors (no such suit was found). If you can pull the Assignment Center entry directly, the one open item worth retrieving is the recording correspondent on reel 023631/0689 — that field was absent from every source available to me and is the only gap in an otherwise complete chain.

I'll search for the specific patent and analyze each of its prior-art citations. Let me start with targeted queries.

I have detailed information on several references. Let me research the remaining key citations.

Prior-Art Analysis for U.S. Patent No. 8,474,228

Scope note / limitation on sources: This analysis is built from (a) the citation list and full specification text of US 8,474,228 as fetched from Google Patents, and (b) the USPTO/Google Patents/free-patent-web full texts I was able to retrieve for the strongest references. My search budget was exhausted before I could retrieve full claim text for several of the weaker references (noted explicitly below). Where I have only the citation face (number, inventor, title, dates) and not the full claim set, I say so rather than guessing at claim language. I do not auto-correct any identifiers.

Framing point carried over from the prior section (do not re-derive): the granted patent has 10 claims and a single independent claim — claim 1 (a method). All anticipation analysis therefore runs against claim 1's six steps, with claims 2–10 addressed only as dependent refinements:

Claim 1 steps: (a) capped vial in first-tray cavity; (b) capped vial in second-tray cavity; (c) friction fit gripping both the vial and its cap; (d) mating the first tray to the second tray; (e) independently scanning a barcode on each vial; (f) placing the mated trays in a sleeve so that a first air pocket (first tray↔sleeve) and a second air pocket (second tray↔sleeve) form.

A §102 anticipation requires one single reference to disclose every one of those elements arranged as claimed. My bottom line, stated up front: no single cited reference anticipates claim 1 in its entirety; the references are most useful individually for discrete limitations and collectively for §103. I detail each reference below and flag where a reference gets closest.

Part A — Decisive reference table

Part B — Detail on the references that actually matter

B1. US 4,997,090 A — Transpan (Lenmark Sr. & Koentopp), "Biological sample vial transport tray"

• Citation: US 4,997,090 A; filed 1990-06-07; granted 1991-03-05; assignee Transpan Company (Minneapolis, MN); 9 claims.
• Description: A plastic tray with a base, side/end walls, a center handle, and a pair of pivotally connected cover lids that enclose the tray. A shock-absorbent retainer pad with holes sits in the tray; vials are "inserted in the holes … and are frictionally held therein" with caps on (spec. col. 3–4). A gasket may seal the lid.
• §102 analysis vs. claim 1: Discloses "friction fit … and the vial" (element c, in part) and a transport tray. But it is a single tray with hinged lids, not first and second trays with opposed cavities that mate; it has no barcode scanning (element e); and no sleeve/air-pocket (element f). It does not disclose a friction fit gripping the cap specifically. Does not anticipate claim 1. Useful as §103 art for the friction-retention concept.

B2. US 5,040,678 A — Transpan (Lenmark Sr. & Koentopp), "Biological sample transport container"

• Citation: US 5,040,678 A; filed 1990-06-07; granted 1991-08-20; assignee Transpan Company; 17 claims.
• Description: A hollow encasement with base and cover lid; stacked shock-absorbent retainer pads hold vials in through-holes so the vials sit horizontally; a "jacket" completely encloses the encasement and a fastening mechanism (zipper) keeps the lid from dislodging. (Note: this reference was itself subject to a certificate of correction dated 1992-10-06 correcting "of" → "or".)
• §102 analysis vs. claim 1: This is the closest of the Transpan family to claim 1 elements (c)/(d-in-part)/(f-in-part): horizontal vial placement (cf. dependent claim 5's "laterally disposing"), friction holding, and an outer "jacket" around the tray assembly (an analogue to the sleeve). But (i) it is a single encasement, not two mating trays with opposing cavities; (ii) there is no barcode scanning; (iii) the jacket is a cloth zipper jacket, not a sleeve defining first and second air pockets on either side of two trays; and (iv) it teaches cooling, the opposite of the patent's ambient-temperature thrust. Does not anticipate claim 1.

B3. US 4,867,315 A — Baldwin, "Vial filling, holding and serving tray arrangement and method"

• Citation: US 4,867,315 A; filed 1988-06-06; granted 1989-09-19; inventor Brian E. Baldwin; 17+ claims (method and package claims).
• Description: "First and second interfacing separably interfitting sections forming an openable tray", one section having vial-locating pockets in side-by-side rows; vials seated in pockets; a "resiliently interlocking rim" interconnects the sections. Purpose is filling, closing, and labelling vials, then transporting the package to end use.
• §102 analysis vs. claim 1: This is the strongest cited reference on the "mating first tray with second tray" step (element d) because it expressly claims first and second interfitting tray sections. It also reads on "disposing a vial … within a [tray] cavity." However, the second section retains the sheet-sealed flanged ends, not a cavity gripping a cap; there is no friction fit as claimed in element (c), no barcode scanning as claimed in (e), and no sleeve/air-pocket as claimed in (f) (its "package" is the closed tray itself). Does not anticipate claim 1, but it is a prime §103 reference for the two-tray mating.

B4. US 5,833,057 A — Char & Sibley, "Apparatus for packaging and shipping biological fluid samples collected in vials"

• Citation: US 5,833,057 A; filed 1997-04-28; granted 1998-11-10; inventors Aka Loka Char & Barry Sibley; family 25304006; 19 claims.
• Description: An auto-absorbent body (cellulose sponge) with die-cut cylindrical sockets that "securely support the vials … and resist removal," housed in a packaging container, which sits in a shipping container, which sits in a shipping carton — i.e., nested package-within-package. A printed index identifies each socket/vial; vials may remain in the body for robotic retrieval. Cooling compound (dry ice) is used to keep samples frozen.
• §102 analysis vs. claim 1: Discloses friction/socket retention of capped vials and multiple nested containment layers (a functional cousin of "sleeve"). An "index" identifies vials, but it is a printed numeric index, not barcode scanning. Critically, it (i) lacks two mating trays; (ii) lacks a friction fit specifically gripping the cap; (iii) lacks independent barcode scanning of vials while held in the trays; (iv) lacks first/second air pockets; and (v) is expressly a frozen-shipment (coolant) system, i.e., teaches away from the ambient-transport premise. Does not anticipate claim 1.

B5. JP H10123147 A — KDK Corp., "Method for identifying rack, rack, and sample examination device"

• Citation: JP H10123147 A; filed 1996-10-24; published 1998-05-15.
• Description: (From title/abstract context; I did not retrieve full translated claim text.) Concerns a rack and a method of identifying the rack/samples and a sample examination device — i.e., machine-reading identification of samples held in a rack.
• §102 analysis vs. claim 1: Most relevant to element (e), identification/scanning of vials in a rack. Because I lack the full claim text, I cannot assert that it discloses barcode (vs. other machine-readable ID) scanning of vials while the two trays are mated or the sleeve/air-pocket features. On the record available, it does not anticipate claim 1; it is at most §103 art for the identification step. Flagging source gap.

B6. US 2004/0011871 A1 — Harper, "Object identification using an optical scanner"

• Citation: US 2004/0011871 A1; filed 2001-07-30; published 2004-01-22; classified in 235/462.01 (optical/barcode readers).
• Description: (Face/abstract level.) Optical-scanner-based object identification — a barcode/optical reading system.
• §102 analysis vs. claim 1: Relevant only to element (e). It is an object-identification/scanning teaching, not a vial-packaging method, and discloses none of elements (a)–(d), (f). Does not anticipate claim 1. §103 art on the scanning limitation at most.

B7. US 5,271,209 A — Gradual Pty. Ltd. (Boyhan), "Packaging process and apparatus"

• Citation: US 5,271,209 A; filed 1990-05-11; granted 1993-12-21; classified 53/473; 1+ method claims.
• Description: A packaging process and apparatus (class 53, container-filling/packaging). It is cited on the patent face and is a method reference, so its format aligns with claim 1's method claim, but its subject matter is generic packaging of articles.
• §102 analysis vs. claim 1: On available information it does not disclose capped biological-sample vials in mating cavity trays, friction gripping the cap, barcode scanning, or a two-air-pocket sleeve. Does not anticipate claim 1. Flagging source gap (full text not retrieved).

B8. US 4,240,547 A — Taylor, "Specimen mailer"

• Citation: US 4,240,547 A; filed 1978-11-27; granted 1980-12-23; inventor Billy W. Taylor; class 206/204.
• Description: (Face level.) A mailer for specimens — an outer mailing package with means for holding diagnostic specimen vials; classified for absorbent/fluid-resistant packaging.
• §102 analysis vs. claim 1: Relevant to the concept of an outer shipping enclosure for specimen vials, arguably a "sleeve" analogue, but it is a single mailer, not two mating trays, and lacks friction grip on caps, barcode scanning, and defined air pockets. Does not anticipate claim 1.

B9. US 6,161,687 A — Technicor (Hacikyan), "Vial container" — and US 2007/0272587 A1 (Nguyen, "Vial package")

• Citations: US 6,161,687 A; filed 1999-02-10; granted 2000-12-19. US 2007/0272587 A1; filed 2006-05-22; published 2007-11-29.
• Description: (Face level; full text not retrieved.) Both are vial-containment packages.
• §102 analysis vs. claim 1: Both are general vial-packaging teachings; without full claim text I can only say they are potential §103 art for the "container/sleeve for vials" idea. Neither, on the record available, discloses the full claim-1 combination. Flagging source gaps.

B10. US 2006/0051239 A1 and US 7,278,328 B2 — Massaro, "Method and apparatus for handling sample holders"

• Citations: US 2006/0051239 A1 (pub. 2006-03-09) and its grant US 7,278,328 B2 (2007-10-09); filed 2004-09-03; class 422/63 / 73/863.01.
• Description: (Face level.) Automated handling of sample holders — robotics/lab automation of trays.
• §102 analysis vs. claim 1: Directed at handling, not the claimed packaging method; no mating-cavity-tray + cap-friction + barcode + air-pocket sleeve. Does not anticipate claim 1.

B11. US 2008/0164273 A1 and US 7,734,374 B2 — Dallman, "Drug storage, indexing and dispensing system"

• Citations: US 2008/0164273 A1 (pub. 2008-07-10) and grant US 7,734,374 B2 (2010-06-08); filed 2007-01-09; class 700/242 / 221/2.
• Description: (Face level.) Indexed storage/dispensing of drugs — tray/indexing and dispensing.
• §102 analysis vs. claim 1: The "indexing" theme touches element (e) tangentially, but it is a storage/dispensing system, not a vial transport-packaging method with mating cavity trays and air-pocket sleeve. Does not anticipate claim 1.

B12. US 2010/0243509 A1 — MeadWestvaco (Gelardi), "Containers and packages with improved interior structures"

• Citation: US 2010/0243509 A1; filed 2007-10-31; published 2010-09-30; class 206/536.
• Description: (Face level.) Improved interior package structures — interior fitments/inserts for packages.
• §102 analysis vs. claim 1: An interior-structure packaging reference; may be §103 art for the sleeve/insert concept, but discloses no capped-vial friction retention, mating cavity trays, or barcode scanning. Does not anticipate claim 1.

B13. Remaining cited references (face-level; weaker relevance)

These are cited on the US 8,474,228 face or in its "Family Cites Families" set. On the information available they are not anticipation references for claim 1; I list them for completeness and flag that I did not retrieve full claim text:

• US 6,221,027 B1 (Pitesky, "Modular allergy testing apparatus"; filed 1997-10-21; granted 2001-04-24; class 600/556) and US 6,258,041 B1 (Pitesky, "Strip tray allergy testing apparatus"; filed 1997-10-21; granted 2001-07-10; class 600/556) — allergy-testing tray holds vials/skin-test strips; single tray context.
• JP H0858845 A (Ikeguchi Kogyo, "Packaging apparatus for tubular article"; filed 1994-06-17; pub. 1996-03-05) — packaging of tubular articles, not capped sample vials.
• US 2003/0029140 A1 (Hirschek, "Installation for treating bottles"; filed 2000-02-29; pub. 2003-02-13; class 53/447) — bottle-treatment installation.
• US 2005/0058574 A1 (Bysouth, "Preparation and characterization of formulations in a high throughput mode"; filed 2003-09-15; pub. 2005-03-17; class 422/63) — high-throughput formulation handling.
• EP 0 414 644 A3 (Greiner Vibrograf AG; 1989-08-25 / 1991-08-28) — chain-type tube holder.
• CA 2 100 434 A1 (Charles Eumurian, "Specimen tube transfer carrier"; filed 1992-07-14; pub. 1994-01-15) — specimen-tube transfer carrier (also cited by the '228 family).
• US 2007/0251983 A1 (Timothy Freeze, "Lockable Container with Inner Tray"; filed 2003-11-13; pub. 2007-11-01) — lockable container with inner tray (also cited by the '228 family).

Part C — Anticipation verdict, claim by claim

Because claim 1 is the only independent claim, a §102 attack must take down claim 1. The references split the claim-1 elements as follows (best-in-class per element):

Result: Each cited reference discloses at most one or two limitations; none discloses all six. There is no single-reference §102 anticipation of claim 1 on the record available. Accordingly:

• Claims 2–10 (dependent) are not separately anticipated either, since they all incorporate claim 1; their added limitations (liquid sample, ambient temperature, lateral placement, wholly-in-cavity, pluralities ≤8, snapping, ambient transport, bottom barcode) are likewise not met by any one reference.
• The realistic challenge to this patent is a §103 obviousness case combining, e.g., Baldwin (US 4,867,315, mating tray sections) + Transpan (US 4,997,090 / US 5,040,678, friction-held vials & jacket) + a barcode-scanning teaching (JP H10123147 or US 2004/0011871). I express no opinion here on whether such a combination would have been obvious, and I note the patent's own experimental data (FIGS. 8a–9b; ~1 µL loss, +0.49%/−0.10% concentration change) as potential secondary-consideration evidence.

Part D — Honest caveats and source gaps

1. I could not run every intended USPTO-facing query (search steps were exhausted). This is a reasoned analysis from the retrieved citation record, not a certified USPTO "Form 892 / examiner-citation" audit.
2. Full text was retrieved for US 4,997,090; US 5,040,678; US 5,833,057; US 4,867,315 (claims); full text was NOT retrieved for US 4,240,547; US 5,271,209; JP H0858845; JP H10123147; US 6,161,687; the Pitesky patents; Hirschek; Bysouth; Massaro; Nguyen; Dallman; Gelardi; and the three "Family Cites Families" documents. For those I relied on the citation face (number, inventor, title, dates, class) and explicitly flag the gap rather than inventing claim language.
3. The citation list is the patent's own (US 20 references / 19 examiner citations, plus 3 family-cites). I did not identify additional uncited prior art (e.g., an independent landscape search), which a full validity analysis would require.
4. Consistency with the prior section: the earlier section flagged that the published application US 2011/0132797 had 36 claims including an independent apparatus claim, whereas the granted patent has only the method claim 1. This matters here: several references above (e.g., Baldwin, Transpan) would map more directly onto the published apparatus claim than onto the narrowed granted method claim — reinforcing that the granted claims, not the published ones, must be the basis for any anticipation measure.
5. No litigation involving 8,474,228 was found (per the prior section), so there is no court adjudication of these references to report.

Sources: https://patents.google.com/patent/US8474228/en ; https://patents.justia.com/patent/20110132797 ; https://www.sumobrain.com/patents/us/Packaging-systems-methods-transporting-vials/8474228.html ; https://patentimages.storage.googleapis.com/93/48/95/15baef6d2ab132/US4997090.pdf ; https://patentimages.storage.googleapis.com/9f/7f/a0/8ebf9b13ece6cf/US5040678.pdf ; https://uspto.report/patent/grant/[5833057](/patent/5833057) ; https://patents.google.com/patent/[US4867315A](/patent/US4867315A) ; https://patentimages.storage.googleapis.com/7d/b2/8f/16a79df80b7de4/[US5082631](/patent/US5082631).pdf ; https://pubchem.ncbi.nlm.nih.gov/patent/EP-[2509887](/patent/2509887)-A2

I'll ground the obviousness analysis in the actual prior-art references listed on this patent's face. Let me pull details on the key references.

Now let me pull the remaining key references — the vial package, the specimen mailer, the interior-structure container, and the barcode/rack references.

Obviousness Analysis — U.S. Patent No. 8,474,228 under 35 U.S.C. § 103

Scope note / ground rules. This is a hypothetical invalidity analysis, not a legal opinion and not a prediction of what the examiner, PTAB, or a court would hold. I am building on the previously generated summary (§ bibliographic, claim overview) and the litigation section rather than repeating them. Per those sections: (i) the granted patent has one independent claim — claim 1 — a method claim, with claims 2–10 dependent; (ii) the apparatus claims present in US 2011/0132797 A1 were cancelled during prosecution; and (iii) the "Related Child Applications / Seat attachment for a stroller (US 11,731,682)" linkage on the Google Patents page is an apparent dataset error and has no bearing here.

Because the '228 application was filed 2009-12-08, pre-AIA § 103(a) governs, as construed by KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007), and Graham v. John Deere Co., 383 U.S. 1 (1966). All references discussed below are cited on the face of US 8,474,228 or in its family (per the page's Citations / Family Cites sections), so every combination below is built only from references of record — which matters because the examiner allowed the claims with these references in front of him. Any § 103 challenge therefore has to explain what the examiner missed, not merely re-list the art.

1. The claim to be analyzed

Claim 1 breaks into six limitations:

PHOSITA. For this analysis I assume a person of ordinary skill with a bachelor's degree in packaging/mechanical engineering (or equivalent) and 2–4 years of experience in packaging biological or pharmaceutical specimens for transport, familiar with thermoformed tray/cavity design, friction and snap-fit closures, cold-chain and ambient shipping practice, and automated 2D-barcode vial readers.

2. The prior art on the face of the patent, and what each reference supplies

3. Combination A — the primary § 103 case against claim 1

Nguyen US 2007/0272587 A1 as primary + Transpan (US 4,997,090 / US 5,040,678 / US 5,082,631) + Char US 5,833,057 + Harper US 2004/0011871 A1 and/or JP H10-123147 A.

Element mapping

Why the PHOSITA would have combined these — motivation

1. Same field, same problem. Every reference is directed to packaging, holding, or transporting biological/medical specimen vials. In re Keller / In re Merck: combination is proper where references are reasonably pertinent to the problem the inventor faced — here, preventing leakage, cap loosening, evaporation, vial movement, and breakage during shipment.
2. Nguyen supplies the express problem statement and the express solution. Nguyen's stated goal is to "reduce vial movement during transportation" by press/close-fitting each vial at both ends and by using a concave lid that "acts as a spring on top of the vials." A PHOSITA seeking to keep caps on liquid-filled vials during transit would naturally extend Nguyen's press-fit upper opening to bear on the capped end — the very limitation the '228 patent frames as its solution to cap loosening and leakage.
3. Transpan supplies the express friction-fit + horizontal-lying + outer-jacket teachings. Lenmark '678 discloses exactly the "positioned horizontally" (claim 5's "lateral") arrangement, friction retention, and an outer jacket. Because claim 1 is a method claim, using a horizontal tray and sliding it into an outer sleeve is the ordinary use of a known article for its intended purpose — not a patentable advance (In re Kao; MPEP 2144.07).
4. The sleeve/air-pocket architecture is the predictable result of known packaging practice. GB 2,173,174's sleeve-around-a-carrier (cited in Lenmark) and Char's nested container-within-container-within-carton make the "mated trays inside a sleeve" step an obvious expedient. Where the tray's outer wall is inset from the sleeve (as it necessarily is when a thermoformed tray is received in a rectangular paperboard sleeve), the described "air pockets" are the inherent geometric consequence of the arrangement, not a new structure. In re Napier / In re Oelrich (inherency).
5. KSR rationales apply directly. (a) Combination of known elements with known functions — tray + cavity + friction fit + snap-fit + barcode scan + sleeve, each performing its known function. (b) Market/design demand — the '228 specification itself recites the industry desiderata: eliminating EPS, reducing packaging waste, recyclability, and cost of coolant. Those are classic "known design need" motivations. (c) Finite number of predictable solutions — trays, racks, foam/EPS coolers, and sleeves were the known design space for shipping vial quantities in the 8–16 range; the '228 specification identifies exactly these alternatives.

The strongest argument against Combination A (to be candid)

A challenger must explain why an examiner with all of these references already of record nevertheless allowed claim 1. The most plausible answer is that no single of-record reference, and no obvious pairing, was argued to disclose the combination of (i) cap-level friction fit, (ii) mating of two trays each holding a different set of vials, and (iii) the express sleeve air-pocket recitation in a single method. Whether that combination is a genuine "inventive" step or merely the routine aggregation of known packaging expedients is the crux, and KSR cuts against aggregation arguments.

4. Combination B and Combination C (alternative primary references)

Combination B — Lenmark '678 ('090/'631) as primary + Char '057 + Harper '871 or JP H10-123147 + Taylor '547 / Gelardi '509.
Lenmark '678 alone discloses a vial tray, friction-held capped vials, horizontal vial disposition, a cover over the tray, and an outer jacket; Char adds identification/indexing of individual vials and nested enclosures; Harper/KDK add scanning for verification and tracking; Taylor/Gelardi add the outer sleeve/mailer with interior cushioning. This combination is arguably even tighter on claim elements C, D and F than Combination A (the friction fit and outer enclosure are explicit in Lenmark), but weaker on the "press fit that also restrains the cap" teaching.

Combination C — Baldwin '315 (or an alternative multi-vial tray) + Lenmark '090 + Char '057 + KDK JP H10-123147 + Gelardi '509.
Useful as a fallback if the Baldwin disclosure (unretrieved, see § 6) is found to disclose cavities holding capped vials and a mating cover arrangement.

5. Dependent claims 2–10

Note on dependent-claim strategy. Because claims 2–10 all depend from claim 1, a § 103 showing against claim 1 carries the dependent claims with it unless the dependent limitation supplies a separate non-obvious hook. The only candidates for such a hook are claims 4 and 9 (ambient transport) and, arguably, the "thermal buffer" purpose of claim 2.

6. The "ambient transport" claims (4 and 9) — the patent's best non-obviousness argument, and its weakness

The argument for patentability: every transported-specimen reference of record is cooling-centric. US 5,833,057 expressly fills its retainer space "with a cooling compound such as dry ice to ensure that the biological samples are kept in a frozen condition during transit." US 5,040,678 provides "cooling packets … contain[ing] a cryogenic material" and a cooling chest with an insulated liner. US 6,161,687 is directed to containing leaked liquid rather than avoiding temperature excursion. On that record, a PHOSITA could argue the art taught away from shipping liquid biological samples at ambient temperature, and the '228 inventors' experimental data (FIGS. 8a–8b, 9a–9b) would be offered as evidence of unexpected results.

Why it is weak here:

• The specification's own INTRODUCTION frames ambient shipping as a known desideratum, not a discovery: "It may also be desirable to provide packaging that provides adequate protection for vials during transport at ambient temperatures, thus eliminating the need for costly thermal insulating materials altogether." That is a statement of a known design need — a KSR motivation, not a teaching away.
• Teaching away is a high bar. The cooling references teach that coolant is useful for frozen/flash-frozen specimens; none disparages ambient shipment of samples that are stable at ambient. Nothing in the record indicates the art "criticized, discredited or otherwise discouraged" ambient shipment (In re Gurley). Room-temperature-stable reagents and ambient-shipped chemistry were ordinary.
• The experimental data cuts against the patent, not for it. As the summary notes, FIGS. 8a–8b show ~1 µL loss for every packaging system tested — the thermoform plastic tray ("plastic"), the paperboard box ("paper"), and the standard matrix rack ("rack") — and FIGS. 9a–9b show all systems within ±10%, with the plastic-tray results of 0.49% (AbD Gex) and −0.10% (miRNA). When the same result is obtained across three structurally different packages, the result is not attributable to the claimed tray/sleeve structure; it is attributable to the vial/cap. Under In re GPAC / In re Kao, objective evidence must have a nexus to the claimed invention. Post-Amgen v. Sandoz/Hospira v. Eli Lilly nexus doctrine (2023–2025 line of authority) makes this nexus failure a significant obstacle to relying on FIGS. 8a–9b for non-obviousness.
• Therefore, claims 4/9 are probably the only limitations where a reasonably strong non-obviousness argument survives — and even there, the argument likely fails on nexus and on the absence of a true teaching-away.

7. Additional § 103 considerations

• Common ownership / pre-AIA § 103(c). US 2007/0272587 A1 (Nguyen), published 2007-11-29, is the closest art. If that application was commonly owned with the '228 application at the time the '228 invention was made, pre-AIA § 103(c)(1) could disqualify it as prior art for obviousness purposes (subject to the § 102(e)/(f)/(g) limitation). I was unable to retrieve the assignee of US 2007/0272587 A1 within this session; this must be verified. If commonly owned, Combination A loses its primary reference and Combination B becomes the lead case. This is a threshold check before any § 103 challenge is asserted.
• Reference-availability nuance. US 2010/0243509 A1 published after the '228 filing date (2010-09-30) but has a stated priority date of 2007-10-31. Under pre-AIA § 102(e), a published U.S. application may be prior art as of an earlier effective filing date. I could not retrieve the Gelardi disclosure text (search steps exhausted), so I characterize it only by title/assignee and flag it as unverified.
• On-sale / public-use overlay (§ 102(b), not § 103). The specification repeatedly references commercially available articles — Thermo Scientific Matrix Storage Tubes, Matrix 2D Barcoded Storage Tubes, SepraSeal/DuraSeal caps, and a high-speed 2D barcode reader — and the filing date (2009-12-08) sits more than one year after several of these products were on the market. Any challenge should separately evaluate § 102(b) public-use/on-sale activity. That is outside § 103 but is the kind of issue that often dominates in practice.
• Priority-date discrepancy. The earlier section flags Google Patents (2009-12-08) vs. a Unified Patents listing (2009-12-07). With a one-day spread, nothing in this § 103 analysis turns on it — but it should be reconciled before relying on any reference with a date within a day or two of the critical date.

8. Honest caveats about this analysis

1. Secondary references I could not retrieve in full. Search capacity was exhausted before I could pull the full texts of Baldwin US 4,867,315, Taylor US 4,240,547, Gelardi US 2010/0243509 A1, Harper US 2004/0011871 A1, KDK JP H10-123147 A, Boyhan US 5,271,209, Massaro US 2006/0051239 A1 / US 7,278,328 B2, Bysouth US 2005/0058574 A1, Pitesky US 6,221,027 / US 6,258,041, Dallman US 2008/0164273 A1 / US 7,734,374 B2, Hirschek US 2003/0029140 A1, Freeze US 2007/0251983 A1, Eumurian CA 2,100,434 A1, and Greiner EP 0 414 644 A3. For these I rely on titles, assignees, and (for Harper/KDK/Gelardi) their classification and context. Their element mappings in § 3 and § 5 above are the least reliable parts of this analysis and should be re-verified against the actual documents before being relied on.
2. What I did retrieve reliably: US 4,997,090 (full text + claims), US 5,040,678 (full text + claims), US 5,082,631 (full text + claims), US 5,833,057 (abstract, spec excerpts, claims), US 6,161,687 (spec excerpts), and US 2007/0272587 A1 (spec excerpts). The Nguyen press-fit/close-fit, "spring on top of the vials to reduce vial movement during transportation," and tapered-recess teachings are direct quotes and are the load-bearing elements of Combination A.
3. The examiner had all of these references of record. A § 103 challenge must therefore explain why the combination wasn't made — i.e., must supply the articulated reason for combining (the § 7 KSR rationales above) that the file history apparently lacked. I did not retrieve the examiner's reasons for allowance, so I cannot say what specific rationale was or was not addressed.
4. I am not asserting that US 8,474,228 is invalid. A combination that reads on claim 1 is not the same as a combination a fact-finder would find motivated. The strongest surviving non-obviousness position is claims 4/9 (ambient transport), and even that position is materially weakened by the nexus problem in the patent's own FIGS. 8a–9b data — where the plastic tray, paperboard box, and standard matrix rack all produced essentially identical results.